pentoxifylline has been researched along with Albuminuria in 18 studies
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of pentoxifylline and captopril on urinary albumin excretion (UAE) rate in non-hypertensive diabetic patients with microalbuminuria." | 9.11 | Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2005) |
| "To investigate the anti proteinuric effect of pentoxifylline in diabetic patients, we prospectively studied in 25 hypertensive type 2 diabetic patients with persistent microalbuminuria and normal renal function the impact of combining pentoxifylline with an angiotensin converting enzyme inhibitor, lisinopril, on urinary albumin excretion and compared the results with those obtained in a control group of 25 type 2 diabetic patients treated with lisinopril only." | 9.10 | Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. ( Harmankaya, O; Seber, S; Yilmaz, M, 2003) |
| "We searched bibliographic databases for trials involving pentoxifylline that reported proteinuria, glomerular filtration rate, or blood pressure." | 8.84 | The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. ( Akbari, A; Doucette, S; Fergusson, D; Knoll, G; McCormick, BB; Sydor, A, 2008) |
| "Pentoxifylline is a drug with hemorheological actions used in the management of microcirculatory abnormalities, such as those usually seen in diabetic patients." | 6.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| "Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease." | 6.44 | Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2008) |
| "To compare the efficacy of pentoxifylline and captopril on urinary albumin excretion (UAE) rate in non-hypertensive diabetic patients with microalbuminuria." | 5.11 | Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2005) |
| "To investigate the anti proteinuric effect of pentoxifylline in diabetic patients, we prospectively studied in 25 hypertensive type 2 diabetic patients with persistent microalbuminuria and normal renal function the impact of combining pentoxifylline with an angiotensin converting enzyme inhibitor, lisinopril, on urinary albumin excretion and compared the results with those obtained in a control group of 25 type 2 diabetic patients treated with lisinopril only." | 5.10 | Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. ( Harmankaya, O; Seber, S; Yilmaz, M, 2003) |
| "From the available evidence, pentoxifylline seems to offer some beneficial effects in renal function improvement and reduction in albuminuria and proteinuria, with no obvious serious adverse effects for patients with DKD." | 4.88 | Pentoxifylline for diabetic kidney disease. ( Li, J; Liu, GJ; Shan, D; Wu, HM; Yuan, QY; Zhou, RL, 2012) |
| "We searched bibliographic databases for trials involving pentoxifylline that reported proteinuria, glomerular filtration rate, or blood pressure." | 4.84 | The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. ( Akbari, A; Doucette, S; Fergusson, D; Knoll, G; McCormick, BB; Sydor, A, 2008) |
| " The aim of this study is to evaluate the direct effects of losartan and/or pentoxifylline on expression of renal DDAH-1 and its relation to oxidative stress in the setting of albuminuria." | 3.79 | Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy. ( Ahn, JS; Cho, JH; Choi, JY; Hyun, SH; Kim, CD; Kim, YL; Oh, EJ; Oh, SH; Park, SH; Ryu, HM; Yoon, SH, 2013) |
| "Pentoxifylline treatment (400 mg/twice a day) or standard treatment." | 2.90 | Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. ( Barbieri, D; Carbayo, J; de Jose, AP; de Morales, AM; Delgado, A; Goicoechea, M; Luño, J; Verdalles, U; Verde, E, 2019) |
| "Pentoxifylline is a drug with hemorheological actions used in the management of microcirculatory abnormalities, such as those usually seen in diabetic patients." | 2.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| "Many patients with intermittent claudication are encouraged to exercise." | 2.67 | Pharmacological reduction of the systemically damaging effects of local ischaemia. ( Gosling, P; Paterson, IS; Sanghera, K; Shearman, CP; Simms, MH; Smith, FC; Tsang, GM, 1994) |
| "Pentoxifylline (PTF) has anti-inflammatory properties, which may be beneficial for diabetic nephropathy (DN)." | 2.52 | Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. ( Shen, Y; Sun, ZL; Tian, ML; Zha, Y, 2015) |
| "Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease." | 2.44 | Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, YC | 1 |
| Chang, YH | 1 |
| Yang, SY | 1 |
| Wu, KD | 1 |
| Chu, TS | 1 |
| Navarro-González, JF | 1 |
| Sánchez-Niño, MD | 1 |
| Donate-Correa, J | 1 |
| Martín-Núñez, E | 1 |
| Ferri, C | 1 |
| Pérez-Delgado, N | 1 |
| Górriz, JL | 1 |
| Martínez-Castelao, A | 1 |
| Ortiz, A | 1 |
| Mora-Fernández, C | 1 |
| de Morales, AM | 1 |
| Goicoechea, M | 1 |
| Verde, E | 1 |
| Carbayo, J | 1 |
| Barbieri, D | 1 |
| Delgado, A | 1 |
| Verdalles, U | 1 |
| de Jose, AP | 1 |
| Luño, J | 1 |
| Park, SH | 1 |
| Hyun, SH | 1 |
| Ryu, HM | 1 |
| Ahn, JS | 1 |
| Oh, SH | 1 |
| Oh, EJ | 1 |
| Yoon, SH | 1 |
| Choi, JY | 1 |
| Cho, JH | 1 |
| Kim, CD | 1 |
| Kim, YL | 1 |
| He, T | 1 |
| Cooper, ME | 1 |
| Tian, ML | 1 |
| Shen, Y | 1 |
| Sun, ZL | 1 |
| Zha, Y | 1 |
| Laczy, B | 1 |
| Cseh, J | 1 |
| Mohás, M | 1 |
| Markó, L | 1 |
| Tamaskó, M | 1 |
| Koszegi, T | 1 |
| Molnár, GA | 1 |
| Wagner, Z | 1 |
| Wagner, L | 1 |
| Wittmann, I | 1 |
| Shan, D | 1 |
| Wu, HM | 1 |
| Yuan, QY | 1 |
| Li, J | 1 |
| Zhou, RL | 1 |
| Liu, GJ | 1 |
| Harmankaya, O | 1 |
| Seber, S | 1 |
| Yilmaz, M | 1 |
| Rodríguez-Morán, M | 3 |
| Guerrero-Romero, F | 3 |
| Navarro, JF | 2 |
| Milena, FJ | 1 |
| Mora, C | 2 |
| León, C | 1 |
| García, J | 1 |
| McCormick, BB | 1 |
| Sydor, A | 1 |
| Akbari, A | 1 |
| Fergusson, D | 1 |
| Doucette, S | 1 |
| Knoll, G | 1 |
| Paniagua-Sierra, JR | 1 |
| García-Bulnes, G | 1 |
| Salas-Ramírez, M | 1 |
| Amato, D | 1 |
| Tsang, GM | 1 |
| Sanghera, K | 1 |
| Gosling, P | 1 |
| Smith, FC | 1 |
| Paterson, IS | 1 |
| Simms, MH | 1 |
| Shearman, CP | 1 |
| Solerte, SB | 1 |
| Fioravanti, M | 1 |
| Cerutti, N | 1 |
| Severgnini, S | 1 |
| Locatelli, M | 1 |
| Pezza, N | 1 |
| Rondanelli, M | 1 |
| Trecate, L | 1 |
| Balza, G | 1 |
| Ferrari, E | 1 |
| Gorson, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients: Assessment of Urine Podocin, Urine Nephrin, Urine Interleukin-6, Urine KIM-1, Plasma Renin, and Albuminuria[NCT05298163] | 120 participants (Anticipated) | Interventional | 2022-04-30 | Not yet recruiting | |||
| Interaction of Polymorphism rs35652124 With Curcumin Supplementation on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function in Patients With Early Diabetic Nephropathy[NCT03262363] | Phase 2/Phase 3 | 176 participants (Anticipated) | Interventional | 2018-08-01 | Not yet recruiting | ||
| Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease[NCT01847313] | Phase 3 | 20 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Spot urine sample for MCP-1 and creatinine (NCT01847313)
Timeframe: Up to 26 weeks
| Intervention | ng/mmol (Mean) |
|---|---|
| Liraglutide | 27.9 |
| Control | 24.3 |
Serum sample for sCD163 (NCT01847313)
Timeframe: Up to 26 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| Liraglutide | 82 |
| Control | 84 |
Spot urine sample for MCP-1 and creatinine (NCT01847313)
Timeframe: Up to 26 weeks
| Intervention | pg/mmol (Mean) |
|---|---|
| Liraglutide | 27.9 |
| Control | 24.3 |
Albuminuria as Measured by 24 Hour Albumin Excretion Rate (NCT01847313)
Timeframe: Up to 26 weeks
| Intervention | µg/min (Mean) |
|---|---|
| Liraglutide | 144.1 |
| Control | 132.4 |
5 reviews available for pentoxifylline and Albuminuria
| Article | Year |
|---|---|
Update of pathophysiology and management of diabetic kidney disease.
Topics: Albuminuria; Biomarkers; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failure, Chroni | 2018 |
Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Press | 2015 |
Pentoxifylline for diabetic kidney disease.
Topics: Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropathies; Humans; Pentoxifylline | 2012 |
Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes.
Topics: Albuminuria; Animals; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Glomeru | 2008 |
The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diabetic Nephropat | 2008 |
7 trials available for pentoxifylline and Albuminuria
| Article | Year |
|---|---|
Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.
Topics: Adult; Aged; Albuminuria; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2018 |
Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Cardiovascular Diseases; Creatinine; Disease Progression; Foll | 2019 |
Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus.
Topics: Albuminuria; Anticoagulants; Autonomic Nervous System; Blood Pressure; Body Mass Index; Creatinine; | 2009 |
Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients.
Topics: Aged; Albumins; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; C | 2003 |
Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chi-Square Distribution; Diabetes | 2005 |
Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Do | 1995 |
Pharmacological reduction of the systemically damaging effects of local ischaemia.
Topics: Aged; Albuminuria; Capillary Permeability; Double-Blind Method; Exercise Test; Exercise Tolerance; F | 1994 |
6 other studies available for pentoxifylline and Albuminuria
| Article | Year |
|---|---|
Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy.
Topics: Acetylglucosaminidase; Albuminuria; Amidohydrolases; Angiotensin II Type 1 Receptor Blockers; Animal | 2013 |
Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Free Radi | 2014 |
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G | 2006 |
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G | 2006 |
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G | 2006 |
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G | 2006 |
Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Blood Viscosity; Diabetic Angiopathies; Female; Fibrinogen | 1997 |
Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases.
Topics: Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic | 1998 |
Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy.
Topics: Albuminuria; Diabetic Nephropathies; Humans; Pentoxifylline; Proteinuria; Tumor Necrosis Factor-alph | 1999 |